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Cancer is the leading cause of disease related death in teenagers
and young adults (TYAs) in Western countries.1 2 In the UK,
cancer in TYAs accounts for 9% and 15% of all male and female
deaths respectively, and its incidence has risen by 19% since
the mid-1990s, leading to 2300 new cases a year between 2011
and 2013.1 In Japan it accounted for nearly 7000 deaths between
2000 and 2006.3 TYA cancer survivors are likely to live for
many decades but are at risk of late effects of their treatment.
This article provides information for generalists on late effects
of anticancer chemotherapy (see infographic and supplementary
table A) that may affect quality of life. Radiotherapy related
effects are not discussed but are summarised elsewhere.4
Defining teenagers and young adults
There is no internationally accepted age definition for TYAs.
In the UK, TYA age is 15-24 years, whereas the US National
Cancer Institute defines adolescents and young adults as aged
15-39 years. In this review we use the UK definition of 15-24
years.
Types and prognoses of cancer in TYAs
Table 1⇓ lists the most common cancers seen in TYAs. The
most common cancers seen in this age group are lymphomas,
carcinomas (such as breast, bowel, cervix, and thyroid), and
germ cell tumours. Survival rates for these TYA cancers are
generally good, with five year survival around 85%.5 Five year
survival for Hodgkin’s lymphoma and germ cell tumours is
more than 90%, but sarcomas such as osteosarcoma (60%
survival) carry worse prognoses.6
Chemotherapy plays a major role in the treatment of these
cancers, and TYAs are potentially exposed to a wide range of
chemotherapy agents, each with distinct late effects. A
comprehensive literature review highlighted that these effects
are generally different from those seen in younger children and
adults, specifically in terms of cardiac toxicity, second
malignancies, pulmonary complications, and psychosocial
difficulties.7 The reasons for this are not fully established, but
it is partly because younger patients receive more intensive
chemotherapy regimens and usually live longer, and thus have
more time to develop late effects. There remain several
important unanswered questions about cancer treatment in
TYAs, some of which are detailed in box 1.
What are the late effects of
chemotherapy?
Cardiovascular disease
Chemotherapy is associated with delayed cardiovascular
complications including coronary artery disease, ventricular
failure, and hypertension.8 A Danish cohort study of more than
43 000 TYA cancer survivors found an absolute excess risk of
up to 400 extra hospitalisations due to cardiovascular disease
per 100 000 person-years in survivors compared with the control
group.9 A similar US study identified a twofold increased risk
of cardiovascular disease, which adversely affected survival.10
These associations have been confirmed in specific cancer
subtypes such as Hodgkin’s lymphoma and testicular cancer,11 12
where treatment regimens often contain anthracyclines and
cisplatin.
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Infographic: Outline of the late effects of anticancer chemotherapy and their management
Table A: Summary of late effects of anticancer chemotherapy in teenagers and young adults
Table B: Comparison of cancer survivorship initiatives for children and young adults in different developed countries
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;354:i4567 doi: 10.1136/bmj.i4567 Page 1 of 8
Practice
PRACTICE
What you need to know
• Side effects of anticancer chemotherapy in teenagers and young adults (TYAs) may occur decades after initial treatment
• Ensure patients and care providers have access to details of the treatment received and the potential side effects that may occur
• Have a low threshold for suspicion of second cancers and discuss participation in routine cancer screening programmes
• Actively ask about psychosocial issues in TYAs at follow-up
• Offer referral to fertility preservation services to all TYAs before cytotoxic chemotherapy
Sources and selection criteria
This article is an evidence based review of late effects of chemotherapy in teenagers and young adults (TYAs). Our review encompasses
studies using all age ranges termed as TYA or adolescents and young adult (AYA). We searched PubMed and the Cochrane databases
between 1990 and 2016 using the search terms “teenage and young adult cancer, adolescent and young adult cancer, TYA, AYA, late
effects, chemotherapy, survivorship” to identify observational studies, randomised trials, meta-analyses, and systematic reviews.
Box 1: Unanswered questions about cancer treatment in teenagers and young adults (TYAs)
• What is the optimal fertility preservation strategy for girls and young women?
• Should TYAs with cancer be treated with the same chemotherapy schedules as children or adults with cancer?
• How will the expanding use of targeted drugs change late effects seen after chemotherapy in TYAs?
The estimated risk of cardiac complications in TYAs is
compounded by the fact that some patients will also receive
mediastinal radiotherapy. In a study of Hodgkin’s lymphoma
survivors, the actuarial risk of congestive heart failure 25 years
after diagnosis was 0.4%with non-anthracycline chemotherapy
without mediastinal radiotherapy, 7.5%with non-anthracycline
chemotherapy and concurrent mediastinal radiotherapy, and
10.7% with anthracyclines and mediastinal radiotherapy.11
Identifying and managing cardiovascular
complications
Regardless of therapy received, offer all TYA cancer survivors
lifestyle advice to reduce their risk of cardiovascular disease.
These recommendations are summarised in the infographic
along with potential symptoms and monitoring advice, and are
based on consensus guidelines. Robust evidence showing the
effectiveness of prevention strategies does not yet exist.
Consider coronary artery disease in all patients who present
with chest pain regardless of age if they have a history of
chemotherapy. There are no standardised guidelines for
ventricular function screening after chemotherapy, but offer this
to high risk patients, such as those with a history of
anthracyclines or mediastinal radiotherapy. Systolic function
can be assessed by echocardiography or a MUGA (multigated
acquisition) scan (infographic).4 Offer women with any of the
risk factors above who become pregnant echocardiography in
the second trimester. For the management of left ventricular
dysfunction, the best evidence supports ACE inhibitors with β
blockers.13 14 A recent, single centre, prospective study of 2625
patients showed that early detection and therapy for
anthracycline induced cardiac failure led to substantial recovery
of cardiac function.15
Fertility
Loss of fertility can be distressing to cancer survivors.16 17
Chemotherapy induced infertility occurs primarily due to dose
dependent gonadal toxicity, and alkylating agents such as
cyclophosphamide and procarbazine are often implicated.18 For
example, the MOPP (Mustargen, Oncovin, procarbazine,
prednisone) regimen for treating Hodgkin's lymphoma included
alkylating agents and led to 20% amenorrhoea rates in women.19
The Childhood Cancer Survivor Study found the relative risk
of long term survivors becoming pregnant was 0.81 compared
with healthy sibling controls. TYAs comprised 20% of the study
cohort.20
The risk to fertility after chemotherapy generally increases with
age at treatment.21 22 In a study of women with Hodgkin's
lymphoma, the cumulative risk of premature menopause five
years after treatment was higher among those aged 22-28 years
than in those aged 14-21 years (27.2% v 5.6%).21 Other factors
such as concurrent radiotherapy to the gonadal region 23 also
affect risk. Online risk calculators (see www.fertilehope.org/
tool-bar/risk-calculator.cfm) are available to estimate an
individual patient’s risk. These calculators take into account
gender, cancer type, and treatment and can be used by patients
and health professionals.
Discuss fertility preservation early when agreeing amanagement
plan and, given that treatment plans may change and that few
regimens carry no risk of infertility, offer urgent referral to
fertility preservation services for all TYA patients receiving any
chemotherapy.24 25Options for fertility preservation are outlined
in table 2⇓.
Second malignant neoplasms
Some 17-19% of all new primary cancers occur in cancer
survivors.35 The reason why TYAs are at a greater risk of
developing second malignant neoplasms than older survivors
is unclear but may be because they receive more intensive drug
schedules or because a proportion of patients already have a
genetic predisposition to cancer. Data from the Surveillance,
Epidemiology, and End Results (SEER) database, which
includes details of more than twomillion cancer survivors, show
that the relative risk of second malignant neoplasm decreases
with increasing age at primary cancer diagnosis. For instance,
for the three age groups 0-17, 18-29, and 50-59 years, the
relative risk of second cancer decreased from 6.13 to 2.92 to
1.27 respectively.35 The absolute risk varies by type of both
primary and second malignant neoplasm—primarily a
consequence of the increasing incidence of most cancers with
increasing age.36
Quantifying the risk of secondmalignant neoplasm from specific
chemotherapy regimens is difficult because TYA cancer
survivors may be at risk of second cancers due to genetic or
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environmental factors.37 Moreover, many protocols include
radiotherapy, which itself is carcinogenic.38 However, several
drugs have well established associations with a range of solid
tumours.37 Alkylating agents, topoisomerase II inhibitors, and
antimetabolites have been shown to induce therapy related acute
myeloid leukaemia and myelodysplastic syndrome.39
Currently the only guidelines that exist for screening of second
malignant neoplasms are for women at risk of breast cancer
having received thoracic radiotherapy. This primarily includes
female survivors of Hodgkin’s lymphoma and involves yearly
mammogram and magnetic resonance imaging (MRI) from
eight years after treatment or from age 25 years, whichever
occurs later.4 In other patients, offer advice and support on
lifestyle modifications known to reduce cancer risk including
smoking cessation, alcohol use, sun exposure, diet, and exercise.
TYAs are recommended to follow cancer screening guidelines
applicable to the general population. More intensive screening
may be needed for patients with genetic predisposition to
cancers.
Neurocognitive effects
Neurocognitive changes after chemotherapy can affect
survivorship.40 Antimetabolites and anthracyclines have been
implicated. Although the association has long been established
in childhood cancers,41 emerging evidence shows a similar effect
in TYAs. A retrospective study of more than 2500 cancer
patients aged 11-21 identified deficiencies in emotional
regulation, memory and task efficiency.40 These individuals are
likely to require additional psychological and social support
(see infographic).
Fatigue
Cancer related fatigue is defined as a “distressing, persistent,
subjective sense of physical, emotional, and/or cognitive
tiredness or exhaustion related to cancer or cancer treatment
that is not proportional to recent activity and interferes with
usual functioning.”42 A recent systematic review highlighted
that fatigue can be a disabling problem in younger patients with
cancer, and that urgent research is needed to identify effective
management strategies.43 Fatigue affects 17-29% of all cancer
survivors,44 and can have a great effect on quality of life and
function.44 Reversible causes should be explored (see
infographic). Short bursts of exertion may be more manageable
in these patients, and structured exercise routines, such as a
moderate walking exercise programme, have proved to be
helpful in improving fatigue and decreasing anxiety.44
Psychosocial effects
It is difficult to untangle which psychosocial effects are a direct
side effect of therapy as opposed to the physical and
psychological sequelae of cancer diagnosis and treatment during
a period of life associated with much change. A recent
systematic review on this subject subdivides adolescents and
young adults into three groups based on social needs.45 The
review found that mid-adolescents (15-17 years old) are
principally coping with the physical changes of puberty and the
formation of a social identity,46whereas emerging adults (18-25
years old) are often in the process of leaving their childhood
home, obtaining higher education, and establishing social
connections independent from childhood.
Social effects
A multicentre observational cohort study of TYA cancer
survivors in the US found that, although over 72% of patients
previously in full time employment or education had been able
to return to full time enrolment at 15-35 months after diagnosis,
more than half of this cohort reported difficulties with work or
education, including problems with forgetting, keeping up, and
paying attention.47 In the same study, over 60% of 498 survey
respondents experienced a negative impact of cancer on their
financial situation.48 Financial issues may become apparent
through disruption at work and/or difficulties in obtaining life
insurance policies and mortgages.
Maintaining or forming close or sexual relationships with peers
and potential life partners can be an issue. A negative body
image due to cancer was reported by 61% of patients in the
AYA HOPE study.48 This may be associated with specific
treatment side effects such as alopecia.46Any cognitive problems
related to treatment may also hinder acquisition of social skills
and lead to further problems with self esteem.49
Psychological effects
Psychological issues among TYA cancer survivors include
stress, anxiety, and depression, which may relate to the
disruption of life goals, interpersonal relationships and self
image, as well as fear of disease recurrence.49 In a recent
Australian cross sectional study, 48% of cancer survivors aged
15-25 years fulfilled the diagnostic criteria for post-traumatic
stress disorder (PTSD),50 and the risk factors included female
sex, less social support, and issues with self image and identity.
The parents of these cancer survivors also had a 42% rate of
PTSD, highlighting the need for family based psychological
assessments and interventions.
A Canadian registry based study found that TYA cancer
survivors were more likely to take antidepressants than healthy
controls.51 Social isolation is also observed among TYA cancer
survivors, who may wish to connect with other TYAs with
similar experiences.52 However, this may cause negative
psychological effects if peers relapse or die.
How can we best manage the psychosocial
effects?
The US National Comprehensive Cancer Network guidelines
recommend that TYAs should be involved in decision making
from an early age, given age-appropriate information, and
specifically asked about their understanding of the information
and for permission to share it with parents and others.53 Patient
empowerment is important in optimising survivorship. TYAs
may also wish to access self help groups or online peer support
to connect with cancer patients or survivors of a similar age, as
well as benefit from advice on how to discuss their diagnosis
with others.52
US data suggest there is inadequate provision of psychological
support to serve the needs of TYA cancer patients,54 although
corresponding UK data are lacking. The UK National Institute
for Health and Care Excellence (NICE) recommends
psychosocial needs assessment for patients up to the age of 24
years, and for their families or carers, and to offer appropriate
specialist support at “key points” of care including long term
follow-up,55 as well as early referral to fertility services.
Offer practical support, including referral to occupational health
and social services (see infographic), and highlight sources of
reliable information. Available resources range from tools for
emotional self help, lists of counsellors, and support material
for carers and family members, to information on fertility
preservation, reasonable adjustments at work, insurance and
mortgage issues, and benefits and financial assistance (such as
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free prescriptions for patients requiring treatment for side effects
from cancer therapy).
How can we personalise long term care?
Given that TYA cancer patients may develop a wide array of
complex late effects, there is an increasing move among care
providers, worldwide, to formulate individualised long term
care plans for patients. These care plans would be developed
between patients and their multidisciplinary care teams at the
end of treatment. These plans can be shared with the patient and
primary care provider and would include detail about the
treatment regimen, potential late effects, and an individualised
plan for monitoring. In the UK this forms part of the recovery
package devised by the National Cancer Survivorship Initiative,
which includes a standardised holistic needs assessment of each
patient after their treatment (including medical, psychological,
and financial assessments) and an initial cancer care review
carried out at the patient’s general practice three to six months
after cancer diagnosis.56 Similar survivorship initiatives have
been launched in other countries, all with the overarching aim
of supporting TYA cancer survivors to live a healthy and
productive life (supplementary table B).
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A patient's perspective
I was diagnosed at 14 years old with stage four Hodgkin's lymphoma and received six rounds of chemotherapy and two weeks of radiotherapy.
After six months in remission, I relapsed and was treated with alternating IEP and ABVD chemotherapy, followed by high dose BEAM
chemotherapy and a stem cell transplant.
During the course of my treatment, I missed almost two full years of education and was unable to take my GCSEs. I have found it far more
difficult to be around people, developing social anxiety and depression, for which I am being treated with medication and cognitive behavioural
therapy. Having self confidence and dealing with my frustration is difficult, and I feel that I am a burden to my friends and family. It may help
to have services within oncology that help with the emotional side effects while within the service, rather than after it.
I’ve also struggled with fatigue and have found it hard to work, even part time, and concentrate on my A-levels. Within the service, there is
not enough focus around fertility, and I have struggled to cope with being infertile, especially since no measures were taken to help prevent
it due to my age. Having osteoporosis has been difficult too. However, the Teenage Cancer Trust has really helped me with my recovery
and finding out how to be a person and not a patient, again.
Lily Anderson—TYA cancer survivor
Additional educational resources for patients
Age-specific
• Teenage Cancer Trust, UK charity (www.teenagecancertrust.org/)—Resources for cancer patients aged 13-24 years, including
information on cancer types and treatments; patient stories by tumour type; advice on talking to peers, family, and doctors; information
for friends and family; links to support programmes and events
• CLIC Sargent, UK charity (www.clicsargent.org.uk/content/young-people)—Resources for cancer patients aged 16-24 years, including
patient stories; Facebook group; online community; information about one-to-one social, emotional, practical, and financial support;
free holidays
Further useful links to sources for support for issues including: emotional support, fertility, body image, relationships, finances
• Teens Unite Fighting Cancer, UK charity (http://teensunitefightingcancer.org/)—Resource for cancer patients aged 13-24 years,
including patient stories; blog; forum; support with provision of real hair wigs; national events
• JTV Cancer Support, UK project with increasing links to other countries (http://jtvcancersupport.com/)—Online film-based resource
for TYA cancer patients providing an extensive collection of videos by patients, their families, and healthcare professionals by cancer
type, geographical region, topic, or “channel”
General
• Cancer Research UK (www.cancerresearchuk.org/)
• Macmillan Cancer Support, UK charity (www.macmillan.org.uk/)
Comprehensive resources including physical and psychosocial coping and support during and after treatment, including financial support;
benefits; grants; mortgages; insurance; travel; fertility preservation; physical and sexual health; emotional help; helpline; online community
Additional educational resources for healthcare professionals
• National Institute for Health and Care Excellence. Improving outcomes in children and young people with cancer (NICE guideline
CSG7). 2005. www.nice.org.uk/guidance/csg7
• Coccia PF, Altman J, Bhatia S, et al. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr
Canc Netw 2012;10:1112-50
• Teenage Cancer Trust. Professional resources. 2012. www.teenagecancertrust.org/about-us/what-we-do/professional-leadership/
professional-resources
• National Institute for Health and Care Excellence. Cancer services for children and young people (NICE quality standard QS55). 2014.
www.nice.org.uk/guidance/qs55/
• National Cancer Intelligence Network. Cancer in children, teenagers and young adults (links to publications). 2010. www.ncin.org.uk/
cancer_type_and_topic_specific_work/cancer_type_specific_work/cancer_in_children_teenagers_and_young_adults/
How patients were involved in the creation of this article
A Facebook group used by teenage and young adult (TYA) cancer survivors in our region was used to ask if any TYAs would be interested
in sharing their views and helping to write the manuscript. One responder has written a patient story while another provided detailed advice
on how to focus the article (in particular to focus on psychosocial aspects of survivorship) and reviewed and made suggestions to the final
version. These comments specifically ensured that the article highlighted that the list of late effects in the infographic did not include every
side effect possible and that the psychological effect of having peers who die during or after treatment is important.
Education into practice
• Do you offer cardiovascular and cancer prevention advice to teenage and young adult (TYA) cancer survivors to help reduce their
risk of late effects such as cardiovascular disease and second cancers?
• Do you know how to refer to local fertility services for TYAs who will receive cytotoxic chemotherapy?
46 Grinyer A. The biographical impact of teenage and adolescent cancer. Chronic Illn
2007;3:265-77. doi:10.1177/1742395307085335 pmid:18083681.
47 Parsons HM, Harlan LC, Lynch CF, et al. Impact of cancer on work and education among
adolescent and young adult cancer survivors. J Clin Oncol 2012;30:2393-400. doi:10.
1200/JCO.2011.39.6333 pmid:22614977.
48 Bellizzi KM, Smith A, Schmidt S, et al. Adolescent and Young Adult Health Outcomes
and Patient Experience (AYA HOPE) Study Collaborative Group. Positive and negative
psychosocial impact of being diagnosed with cancer as an adolescent or young adult.
Cancer 2012;118:5155-62. doi:10.1002/cncr.27512 pmid:22415815.
49 Evan EE, Kaufman M, Cook AB, Zeltzer LK. Sexual health and self-esteem in adolescents
and young adults with cancer. Cancer 2006;107(Suppl):1672-9. doi:10.1002/cncr.
22101 pmid:16906508.
50 McCarthy MC, McNeil R, Drew S, et al. Psychological distress and posttraumatic stress
symptoms in adolescents and young adults with cancer and their parents. J Adolesc
Young Adult Oncol 2016;. doi:10.1089/jayao.2016.0015 pmid:27214245.
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Ongoing research studies (a small selection of ongoing trials for teenagers and young adults from Australian, UK,
and US trial programmes)
• A study looking at how genes may affect the risk of kidney damage in children or young people who have treatment with ifosfamide
(PK 2007 02)
• A pilot randomized controlled trial of the Promoting Resilience in Stress Management (PRISM) intervention for adolescents and young
adults with cancer—Study to investigate the effectiveness of the PRISM intervention, which is aimed at promoting self perceived
resilience and consequently minimise patient distress
• RITHM, resonance imaging trial for heart biomarkers in adolescent/young (AYA) cancer survivors—Study aimed at identifying
asymptomatic patients with cardiovascular disease using MRI
• Mobile health fitness program for adolescent and young adult childhood cancer survivors (TLC FIT)
• Music therapy video development in improving communication, emotional distress, and recovery in adolescents/young adults undergoing
treatment for high-risk cancer and their parents
• Risk of fatigue in adolescent and young adult Hodgkin lymphoma patients
• Care after lymphoma (CALy) trial—Phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care
51 Deyell RJ, Lorenzi M, Ma S, et al. Antidepressant use among survivors of childhood,
adolescent and young adult cancer: a report of the Childhood, Adolescent and Young
Adult Cancer Survivor (CAYACS) Research Program. Pediatr Blood Cancer
2013;60:816-22. doi:10.1002/pbc.24446 pmid:23281214.
52 Kent EE, Parry C, Montoya MJ, Sender LS, Morris RA, Anton-Culver H. “You’re too young
for this”: adolescent and young adults’ perspectives on cancer survivorship. J Psychosoc
Oncol 2012;30:260-79. doi:10.1080/07347332.2011.644396 pmid:22416959.
53 Coccia PF, Altman J, Bhatia S, et al. Adolescent and young adult oncology. Clinical
practice guidelines in oncology. J Natl Compr Canc Netw 2012;10:1112-50.pmid:22956810.
54 Barnett M, McDonnell G, DeRosa A, et al. Psychosocial outcomes and interventions
among cancer survivors diagnosed during adolescence and young adulthood (AYA): a
systematic review. J Cancer Surviv 2016;. doi:10.1007/s11764-016-0527-6 pmid:26920873.
55 National Institute for Health and Care Excellence. Cancer services for children and young
people (NICE quality standard QS55). 2014. https://www.nice.org.uk/guidance/qs55.
56 National Cancer Survivorship Initiative. The recovery package. 2014. http://www.ncsi.org.
uk/what-we-are-doing/the-recovery-package/.
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Tables
Table 1| Top eight cancer types by age group (data from Cancer Research UK)
Teenagers and young adults (15-24 years old)
(2014 new cases/year)
Children (0-14 years old)
(1555 new cases/year)
% of totalCancer type% of totalCancer type
21.0Lymphomas30.1Leukaemia1
19.5Carcinomas26.5Brain, other CNS, and intracranial tumours2
15.4Germ cell tumours10.7Lymphomas3
13.7Brain, other CNS, and intracranial tumours6.3Soft tissue sarcoma4
11.2Malignant melanoma5.3Sympathetic nervous system tumours5
8.8Leukaemias5.3Renal tumours6
5.1Bone tumours4.2Bone sarcoma7
4.0Soft tissue sarcomas3.5Carcinomas and malignant melanoma8
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Table 2| Comparison of fertility preservation strategies in women
DisadvantagesAdvantagesApproximate success rate (%
resulting in live births)
Fertility preservation strategy
Female patients
• Oocyte stimulation andmaturation can take
4-6 weeks
• Delay may be unsuitable for aggressive
cancers requiring urgent chemotherapy
• Requires male partner or sperm donor
• Hormonal ovarian stimulation may be
inappropriate for women with oestrogen
receptor positive breast cancer27
• Well established
• Favourable success rates
• Success rates derived from patients with
subfertility (rates for cancer patients may be
higher)
44.1% (frozen-thawed embryo
transfer)
47.4% (fresh embryo use)26
Embryo cryopreservation
• Lower success rate than embryo use at
present
• Delay may be unsuitable for aggressive
cancers
• Hormonal stimulation may be inappropriate
in breast cancer
• No need for sperm donor
• Clinical pregnancy rates of 4.5-12% per
warmed oocyte in prospective studies
• Success rates likely to increase in future28
5-12%28Mature oocyte cryopreservation
• Experimental
• May reintroduce malignancy
• No delay to chemotherapy
• May be suitable for patients in whom delay
for oocyte stimulation is inappropriate24 25
NAOvarian tissue cryopreservation and
re-implantation
Male patients
• Not possible in patients with pre-existing
azoospermia
• Not possible if patient pre-pubertal
• Most reliable and well established method24
• High rate of successful future sperm use
after advances in IVF and ICSI30
49% fatherhood in cancer
patients using their frozen sperm29
(Rates likely to be higher now
after IVF advances)
Sperm cryopreservation
• Not possible if patient pre-pubertal• Option for patients with pre-existing
azoospermia
42% (single centre study)31Microsurgical testicular sperm
extraction followed by ICSI
(microTESE-ICSI)
• Limited evidence to date
• Not possible if patient pre-pubertal
• Option for patients with pre-existing
azoospermia
39% (single centre study
evidence for obstructive
azoospermia in non-cancer
patients)32
Microsurgical epididymal sperm
aspiration followed by ICSCI
(MESA-ICSI)
• Experimental• Possible future option for pre-pubertal
patients33
NATesticular tissue or spermatogonial
stem cell cryopreservation, in vitro
gametematuration, artificial gametes
Both sexes
• Still no clear consensus in women
• Limited evidence in men
• Meta-analyses indicate may improve future
pregnancy rates, particularly in patients with
breast cancer34
NAGonadal protection using GnRH
agonists
IVF=in vitro fertilisation. ICSI=intracytoplasmic sperm implantation. microTESE=microsurgical sperm retrieval from the testicle. MESA=microsurgical epididymal
sperm aspiration. GnRH=gonadotropin-releasing hormone.
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